Boston Scientific acquires Distal Access' gynaecology, urology portfolio

Boston Scientific announced Tuesday that it acquired Distal Access' gynaecology and urology portfolio for an undisclosed amount, including the latter's Resectr tissue resection device, which is a single-use product designed to remove uterine polyps.

David Pierce, president of Boston Scientific's urology and pelvic health, remarked that "the Resectr device is exactly the type of innovation we need to help make healthcare more cost-effective and accessible." He added that "this acquisition is part of our commitment to advance comprehensive solutions for women's health that can help physicians provide high-quality care."

According to Boston Scientific, the Resectr device, which is compatible with a broad range of hysteroscopes, "allows physicians to treat patients with polyps in an office, hospital or ambulatory surgery centre and reduces the need for investment in additional capital equipment required with traditional surgical tools used in this procedure." The device will be integrated into Boston Scientific's urology and pelvic health business.

Last month, Boston Scientific announced that third-quarter sales rose 11 percent year-on-year to $2.1 billion, with revenue from the company's urology and pelvic health segment growing 26 percent to $248 million.

Did you like this article?